How Ph.D. was paid
$21.9M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Incentive | Pension | Other | Total |
|---|---|---|---|---|---|---|---|
| Christopher S. Boerner, Ph.D.Board Chair and Chief Executive Officer | $1,586,346 | $0 | $16,061,399 | $3,754,684 | $0 | $477,490 | $21,879,919 |
| David V. ElkinsEVP and Chief Financial Officer | $1,140,442 | $0 | $5,981,513 | $1,799,484 | $0 | $256,151 | $9,177,590 |
| Cristian Massacesi, M.D.EVP, Chief Medical Officer, Head of Development | $388,462 | $1,125,000 | $7,853,994 | $660,876 | $0 | $44,618 | $10,072,950 |
| Adam LenkowskyEVP, Chief Commercialization Officer | $1,131,731 | $0 | $6,136,800 | $1,794,732 | $27,060 | $250,029 | $9,340,352 |
| Greg MeyersEVP, Chief Digital and Technology Officer | $1,072,692 | $0 | $4,209,168 | $1,669,036 | $0 | $230,277 | $7,181,173 |
| Samit Hirawat, M.D.Former EVP, Chief Medical Officer, Head of Development | $964,904 | $0 | $5,815,320 | $928,658 | $0 | $2,625,351 | $10,334,233 |
What changed and why
- $21.9MCEO total compensation increased to $21,879,919 in 2025 from $18,787,618 in 2024.
- 35%Growth portfolio revenue contributed 35% to annual incentive plan metrics.
- 30%Non-GAAP operating income accounted for 30% of the annual incentive plan metrics.
- 94%Shareholders approved the 2025 say-on-pay proposal with 94% support.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.